Age-related differences in susceptibility to toxic effects of valproic acid in rats

Journal of Applied Toxicology

Volumn 28, Issue 5, 2008, Pages 628-637

  Espandiari, Parvaneh ^a   Zhang, Jun ^a   Schnackenberg, Laura K ^b   Miller, Terry J ^a   Knapton, Alan ^a   Herman, Eugene H ^a   Beger, Richard D ^b   Hanig, Joseph P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

age related toxicity; biomarkers; stages of development; Valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; NITROGEN; PROTEIN; UREA; VALPROIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EXPOSURE; FEMALE; GROUPS BY AGE; GROWTH RATE; LETHALITY; LIVER; LIVER INJURY; MALE; NONHUMAN; PEDIATRICS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUP (RODENT); RAT; SPECTROSCOPY; SPLEEN; SPRAGUE DAWLEY RAT; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

AGING; ALANINE TRANSAMINASE; ANIMALS; ANTICONVULSANTS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; FEMALE; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLISM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; VALPROIC ACID;

ANIMALIA; RATTUS;

EID: 47549093353     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1314     Document Type: Article

References (47)

1. Anderson GD. 2002. Children versus adults: pharmacokinetic and adverse-effect differences. Review. Epilepsia 43: 53-59.
2. Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LT, Davidson AG. 1990. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 17: 145-148.
3. Bates MD, Balistreri WF. 2004. Development and function of the liver and biliary system. In Nelson Textbook of Pediatrics, Behrman RE, Kliegman RM, Jenson HM (eds). Elsevier Health Sciences: Philadelphia; 1304-1308.
4. Blumer JL, Reed MD. 1992. Principles of neonatal pharmacology. In Pediatric Pharmacology: Therapeutic Principles in Practice, Yaffe SJ, Aranda JV (eds). Lippincott Williams & Wilkins: Philadelphia; 164-177.
5. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. 1982. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19: 315-359.
6. Chuang E, Haber BA. 1998. Bile secretion and its control in the mature and immature organism. In Fetal and Neonatal Physiology, Polin RA, Fox WW (eds). WB Saunders: Philadelphia; 1457-1471.
7. Cloyd JC, Fische JH, Kriel RL, Kraus DM. 1993. Valproic acid pharmacokinetics in children. IV Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin. Pharmacol. Ther. 53: 22-29.
8. Cresteil T. 1998. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit. Contam. 15: 45-51.
9. Cresteil T, Beaune P, Kremers P, Celier C, Guengerich FP, Leroux JP. 1985. Immunoquantification of epoxide hydrolase and cytochrome p-450 isozymes in fetal and adult human liver microsomes. Eur. J. Biochem. 151: 345-350.
10. Cresteil T, Beaune P, Kremers P, Flinois JP, Leroux JP. 1982. Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P 450. Pediatr. Pharmacol. (New York) 2: 199-207.
11. Delgado MR, Riela AR, Mills J, Browne R, Roach ES. 1994. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J. Child Neurol. 9: 311-314.
12. Devilat M, Blumel JE. 1991. Adverse effects of valproic acid in epileptic infants and adolescents. Rev. Chil. Pediatr. 62: 362-366.
13. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. 1989. Valproic acid hepatic fatalities II. US experience since 1984. Neurology 39: 201-207.
14. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. 1987. Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379-385.
15. Eadie MJ, Hoope WD, Dickinson RG. 1988. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. Adverse Drug. Exp. 3: 185-106.
16. Easton KL, Parsons BJ, Starr M, Brien JE. 1998. The incidence of drug-related problems as a cause of hospital admissions in children. Med. J. Aust. 169: 356-359.
17. Faustman EM, Silbernagel SM, Fenske RA, Burbacher TM, Ponce RA. 2000. Mechanisms underlying children's susceptibility to environmental toxicants. Review. Environ. Health. Perspect. 108(Suppl 1): 13-21.
18. Fromenty B, Pessayre D. 1995. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67: 101-154.
19. Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Collins M, Jones J. 1994. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 44: 1418-1422.
20. Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), February 2006, Pharmacology and Toxicology.
21. Granneman GR, Wang SI, Machinist JM, Kesterson JW. 1984. Aspects of the metabolism of valproic acid. Xenobiotica 14: 375-387.
22. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. 1999. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40: 985-991.
23. Heyman, S. 1998. Gastric emptying in children. J. Nucl. Med. 39: 865-869.
24. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. 2001. Incidence of adverse drug reactions in paediatric in/ out-patients: a systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 52: 77-83.
25. Insel PA. 1996. Analgesic-antipyretic and antiinflammatory agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). McGraw-Hill: New York; 632.
26. Kapusnik-Uner, JE, MA Sande, HF Chambers. 1996, Antimicrobial agents. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. McGraw-Hill: New York; 1124-1153.
27. Keane PE, Meldrum BS, Simiand J, Vernieres JC. 1982. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19: 315-359.
28. Kesterson JW, Granneman GR, Machinist JM. 1984. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4: 1143-1152.
29. Leeder JS, Kearns GL. 1997. Pharmacogenetics in pediatrics: implications for practice, new frontiers in pediatric drug therapy. Pediatr. Clin. North Am. 44: 55-77.
30. Lewis JH, Zimmerman HJ, Garrett CT, Rosenberg E. 1982. Valproate-induced hepatic steatogenesis in rats. Hepatology 2: 870-873.
31. Makri A, Goveia M, Balbus J, Parkin R. 2004. Children's susceptibility to chemicals: a review by developmental stage. Rev. J. Toxicol. Environ. Health. B. Crit. 7: 417-435.
32. May RB, Sunder TR. 1993. Hematologic manifestations of long-term valproate therapy. Epilepsia 34: 1098-1101.
33. Ozkara C, Dreifuss FE, Apperson Hansen C. 1993. Changes in red blood cells with valproate therapy. Acta Neurol. Scand. 88: 210-212.
34. Peng HM, TD Porter, XX Ding, Coon MJ. 1991. Differences in the developmental expression of rabbit cytochromes P450 2E1 and 2E2. Mol. Pharmacol. 40: 58-62.
35. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. 1998. Adverse drug reactions: current status. Br. Med. J. 316: 1295-1298.
36. Schnackenberg LK, Jones RC, Thyparambil S, Taylor JT, Han T, Tong W, Hansen DK, Fuscoe JC, Edmondson RD, Beger RD, Dragan YP. 2006. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS 10: 1-14.
37. Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. 1999. Valproate population pharmacokinetics in children. J. Clin. Pharm. Ther. 24: 73-80.
38. Simon D, Penry JK. 1975. Di-N-propylacetate (DPA) in the treatment of epilepsy. Epilepsia 16: 549-573.
39. Stephenson T. 2005. How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. 59: 670-673.
40. Szupera Z, Mezei Z, Kis B, Gecse A, Vecsei L, Telegdy G. 2000. The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. Eur. J. Pharmacol. 387: 205-210.
41. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Jr Kando JC. 1995. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2228 patients at risk. Am. J. Psychiatry 152: 413-418.
42. Tong V, Teng XW, Chang TK, Abbott FS. 2005. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci. 86: 427-435.
43. Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. 1999. Platelet count and function in children receiving sodium valproate. Pediatr. Neurol. 21: 611-614.
44. Waxman DJ, Morrissey JJ, Le Balnc GA. 1989. Female predominant rat hepatic P450 forms (IIE1) and 3(IIA1) are under hormonal regulatory controls distinct from those of sex specific P450 forms. Endocrinology 270: 458-471.
45. Weaver LT, Austin S, Cole TJ. 1991. Small intestinal length: a factor essential for gut adaptation. Gut 32: 1321-1323.
46. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT. 2001. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br. J. Clin. Pharmacol. 52: 547-553.
47. Wershill BK. 1992. Gastric function. In Pediatric Gastrointestinal Disease, vol. 1, Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB (eds). Mosby: St Louis, MO; 71-82.